Correlation of monocyte monolayer assays and posttransfusion survival of Yt(a+) red cells in patients with anti-Yva

R.J. Eckrich; D.M. Mallory; S.G. Sandler

doi:10.21307/immunohematology-2019-795

Abstract

Anti-Yt^a is an antibody to a high-frequency (99.8%) antigen and has been reported to have variable clinical significance. A retrospective review of monocyte monolayer assay (MMA) results on sera from 79 patients with anti-Yt^a was conducted to determine the reliability of this assay to predict the clinical significance of anti-Yt^a. Results of the MMA, other serological tests, and patient transfusion histories were analyzed. The MMA was found to be a reliable predictor of the clinical significance of anti-Yt^a when samples for analysis were collected at least six weeks after initial detection of the antibody. Only 18.2 percent of those examples of anti-Yt^a tested appeared to be clinically significant. Immunohematology 1995;11:81–84.

References

Garratty G. Predicting the clinical significance of alloantibodies and determining the in vivo survival of transfused red cells. In: Judd WJ, Barnes A, eds. Clinical and serological aspects of tramsfusion reactions. Arlington, VA: American Association of Blood Banks, 1982:91–119.
Search in Google Scholar Back to article
Nance SJ, Arndt P, Garratty G. Predicting the clinical significance of red cell alloantibodies using a monocyte monolayer assay. Transfusion 1987;27:449–52.10.1046/j.1537-2995.1987.27688071692.x3686653
Search in Google Scholar Back to article
Shoeppncr-Estey S, Girin J, Mallory D, Davey R, A comparison of the monocyte monolayer assay to the ⁵¹Chromium (⁵¹Cr) red cell survival for determining the clinical significance of red cell alloantibodies (abstract). Blood 1986;68:302a.
Search in Google Scholar Back to article
Baldwin ML, Ness PM, Barrasso C, et al. In vivo studies of long term ⁵¹Cr red cell survival for determining the clinical significance of red cell alloantibodies. Transfusion 1985;25:34–8.10.1046/j.1537-2995.1985.25185116499.x3969699
Search in Google Scholar Back to article
Eaton BR. Morton JA, Pickles MM, White KE. A new antibody. anti-Yt^a, characterizing a blood group antigen of high incidence. Br J Haematol 1956;2:333–41.10.1111/j.1365-2141.1956.tb06707.x13383099
Search in Google Scholar Back to article
Dobbs JV, Prutting DL, AdebahrMA. Allen EH, Alter AA. Clinical experience with three examples of anti-Yt^a. Vox Sang 1968; 15:216–21.10.1111/j.1423-0410.1968.tb01752.x5683382
Search in Google Scholar Back to article
Bettigole R, Hams JP, Tegoli J, Issitt PD. Rapid in vivo destruction of Yt(a+) red cells in a patient with anti-Yt^a. Vox Sang 1968;14:143–6.
Search in Google Scholar Back to article
Gobel U, Drescher KH, Pottgen W, Lehr HJ. A second example of anti-Yt^a with rapid in vivo destruction of Yt^a red cells. Vox Sang 1974;27:171–5.
Search in Google Scholar Back to article
International Committee for Standardization in Hematology. Recommended methods for radioisotope red cell survival studies. Blood 1971;38:378–86.10.1182/blood.V38.3.378.378
Search in Google Scholar Back to article
Issitt PD. Applied blood group serology, 3rd ed. Miami, FL: Montgomery Scientific Publications. 1985:387–8.
Search in Google Scholar Back to article
AuBuchon JP, Brightman A, Anderson HA, Kim B. An example of anti-Yt^a demonstrating a change in its clinical significance. Vox Sang 1988;55:171–5.
Search in Google Scholar Back to article
Davey RJ, Simpkins SS. ⁵¹Chromium survival of Yt(a+) red cells as a determinant of the in vivo significance of anti-Yt^a. Transfusion 1982;21:702–5.
Search in Google Scholar Back to article

Correlation of monocyte monolayer assays and posttransfusion survival of Yt(a+) red cells in patients with anti-Yva

Abstract

Paradigm

My account